| ACh | Acetylcholine |
| AChE | Acetylcholinesterase |
| BChE | Butyrylcholinesterase |
| CCEP | Comprehensive Clinical Evaluation Program |
| CNS | Central nervous system |
| COPD | Chronic obstruction pulmonary disease |
| CW | Chemical warfare |
| DFP | Diisopropyl fluorophosphate |
| DoD | Department of Defense |
| EEG | Electroencephalogram, a measure of brain activity |
| EMG | Electromyography |
| FDA | Food and Drug Administration |
| GABA | Gamma amino butyric acid |
| GI | Gastrointestinal |
| IND | Investigational new drug |
| IOM | Institute of Medicine |
| LD50 | Lethal dose for 50 percent of subjects |
| MCS | Multiple chemical sensitivity |
| NAPP | Nerve Agent Pretreatment Pack |
| NAPS | Nerve Agent Pretreatment System |
| NMJ | Neuromuscular junction |
| NTE | Neurotoxic esterase |
| OP | Organophosphate |
| OPIDN | Organophosphate induced delayed neurotoxicity |
| PAC | Presidential Advisory Commission |
| 2PAM | Pralidoxime, a postexposure treatment for nerve agent protection |
| PB | Pyridostigmine bromide |
| PGW | Persian Gulf War |
| PNS | Peripheral nervous system |
| PON | Paraoxonase |
| PR | Protective ratio; LD50 with treatment divided by LD50 without treatment |
| PTSD | Posttraumatic stress disorder |
| RBC | Red blood cell |
| REM | Rapid eye movement |
| SPECT imaging | Single Photon Emission Computer Tomography, a method of evaluating regional (brain) blood flow at a cross section in time |
| SVN | Sindbis virus strain |